Good and poor adherence: optimal cut-point for adherence measures using administrative claims data

ABSTRACT Objective: To identify the adherence value cut-off point that optimally stratifies good versus poor compliers using administratively derived adherence measures, the medication possession ratio (MPR) and the proportion of days covered (PDC) using hospitalization episode as the primary outcome among Medicaid eligible persons diagnosed with schizophrenia, diabetes, hypertension, congestive heart failure (CHF), or hyperlipidemia. Research design and methods: This was a retrospective analysis of Arkansas Medicaid administrative claims data. Patients ≥18 years old had to have at least one ICD-9-CM code for the study diseases during the recruitment period July 2000 through April 2004 and be continuously eligible for 6 months prior and 24 months after their first prescription for the target condition. Adherence rates to disease-specific drug therapy were assessed during 1 year using MPR and PDC. Main outcome measure and analysis scheme: The primary outcome measure was any-cause and disease-related hospitalization. Univariate logistic regression models were used to predict hospitalizations. The optimum adherence value was based on the adherence value that corresponded to the upper most left point of the ROC curve corresponding to the maximum specificity and sensitivity. Results: The optimal cut-off adherence value for the MPR and PDC in predicting any-cause hospitalization varied between 0.63 and 0.89 across the five cohorts. In predicting disease-specific hospitalization across the five cohorts, the optimal cut-off adherence values ranged from 0.58 to 0.85. Conclusions: This study provided an initial empirical basis for selecting 0.80 as a reasonable cut-off point that stratifies adherent and non-adherent patients based on predicting subsequent hospitalization across several highly prevalent chronic diseases. This cut-off point has been widely used in previous research and our findings suggest that it may be valid in these conditions; it is based on a single outcome measure, and additional research using these methods to identify adherence thresholds using other outcome metrics such as laboratory or physiologic measures, which may be more strongly related to adherence, is warranted.

[1]  Christian R. Dolder,et al.  Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. , 2004, The American journal of psychiatry.

[2]  Timothy W. Smith,et al.  Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[4]  W. Tu,et al.  Association of Refill Adherence and Health Care Use Among Adults with Hypertension in an Urban Health Care System , 2006, Pharmacotherapy.

[5]  Bradley C Martin,et al.  Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  M. Cheang,et al.  Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.

[7]  Jennifer Y. Liu,et al.  Pioglitazone initiation and subsequent hospitalization for congestive heart failure , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[8]  Femida Gwadry-Sridhar,et al.  A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  K. Rajagopalan,et al.  Hospitalization Risks in the Treatment of Schizophrenia: Comparison of Antipsychotic Medications , 2006, Journal of clinical psychopharmacology.

[10]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[11]  M. Weinstein,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[12]  B. Martin,et al.  Contrasting Measures of Adherence with Simple Drug Use, Medication Switching, and Therapeutic Duplication , 2009, The Annals of pharmacotherapy.

[13]  N. Cook Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. , 2008, Clinical chemistry.

[14]  Bradley C Martin,et al.  An Empirical Basis for Standardizing Adherence Measures Derived From Administrative Claims Data Among Diabetic Patients , 2008, Medical care.

[15]  A. Ash,et al.  R2: a useful measure of model performance when predicting a dichotomous outcome. , 1999, Statistics in medicine.

[16]  Marsha A Raebel,et al.  Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.

[17]  David B Lawrence,et al.  Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. , 2005, Diabetes care.

[18]  John D. Voss,et al.  The association between diabetes metabolic control and drug adherence in an indigent population. , 2002, Diabetes care.

[19]  M. Earnest,et al.  The Language of Medication-Taking , 2000, Annals of Internal Medicine.

[20]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[21]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[22]  Michael Kelleher,et al.  Hypertension management: the care gap between clinical guidelines and clinical practice. , 2004, The American journal of managed care.

[23]  M. Valenstein,et al.  Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. , 2007, Psychiatric services.

[24]  S. Iyer,et al.  Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population , 2006, Journal of managed care pharmacy : JMCP.

[25]  Laurel,et al.  Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission , 2002, Medical care.

[26]  Denys T. Lau,et al.  Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. , 2004, Diabetes care.

[27]  Michael H. Kutner Applied Linear Statistical Models , 1974 .

[28]  B. Nightengale,et al.  Relationship of Blood Pressure Control to Adherence With Antihypertensive Monotherapy in 13 Managed Care Organizations , 2006, Journal of managed care pharmacy : JMCP.

[29]  M. Amonkar,et al.  Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis. , 2006, Clinical therapeutics.

[30]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.

[31]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.